Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Mycobacterium tuberculosis drug effects"" wg kryterium: Temat


Tytuł :
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
Autorzy :
Reid, M.J.A. (Michael J A)
Arinaminpathy, N. (Nimalan)
Bloom, A. (Amy)
Bloom, B.R. (Barry R)
Boehme, C. (Catharina)
Chaisson, R. (Richard)
Chin, D.P. (Daniel P)
Churchyard, G. (Gavin)
Cox, H. (Helen)
Ditiu, L. (Lucica)
Dybul, M. (Mark)
Farrar, Jeremy
Fauci, A.S. (Anthony S)
Fekadu, E. (Endalkachew)
Fujiwara, P.I. (Paula I)
Hallett, Timothy
Hanson, C.L. (Christy L)
Harrington, M. (Mark)
Herbert, N. (Nick)
Hopewell, P.C. (Philip C)
Ikeda, C. (Chieko)
Jamison, D.T. (Dean T)
Khan, A.J. (Aamir J)
Koek, I. (Irene)
Krishnan, N. (Nalini)
Motsoaledi, A. (Aaron)
Pai, M. (Madhukar)
Raviglione, M.C. (Mario C)
Sharman, A. (Almaz)
Small, P.M. (Peter M)
Swaminathan, S. (Soumya)
Temesgen, Z. (Zelalem)
Vassall, A. (Anna)
Venkatesan, N. (Nandita)
van Weezenbeek, K. (Kitty)
Yamey, G. (Gavin)
Agins, B.D. (Bruce D)
Alexandru, S. (Sofia)
Andrews, J.R. (Jason R)
Beyeler, N. (Naomi)
Bivol, S. (Stela)
Brigden, G. (Grania)
Cattamanchi, A. (Adithya)
Cazabon, D. (Danielle)
Crudu, V. (Valeriu)
Daftary, A. (Amrita)
Dewan, P. (Puneet)
Doepel, L.K. (Laurie K)
Eisinger, R.W. (Robert W)
Fan, V. (Victoria)
Fewer, S. (Sara)
Furin, J. (Jennifer)
Goldhaber-Fiebert, J.D. (Jeremy D)
Gomez, G.B. (Gabriela B)
Graham, S.M. (Stephen M)
Gupta, D. (Devesh)
Kamene, M. (Maureen)
Khaparde, S. (Sunil)
Mailu, E.W. (Eunice W)
Masini, E.O. (Enos O)
McHugh, L. (Lorrie)
Mitchell, Ellen
Moon, S. (Suerie)
Osberg, M. (Michael)
Pande, T. (Tripti)
Prince, L. (Lea)
Rade, K. (Kirankumar)
Rao, R. (Raghuram)
Remme, Michelle
Seddon, J.A. (James A)
Selwyn, C. (Casey)
Shete, P. (Priya)
Sachdeva, K.S. (Kuldeep S)
Stallworthy, G. (Guy)
Vesga, J.F. (Juan F)
Vilc, V. (Valentina)
Goosby, E.P. (Eric P)
Pokaż więcej
Temat :
Quality of Health Care/standards
Global Health/legislation & jurisprudence
World Health Organization/economics
Mycobacterium tuberculosis/drug effects
Political Systems
Disease Eradication
Research/economics
Health Policy
Health Priorities
Leadership
Mortality
Tuberculosis, Pulmonary/drug therapy
Cost of Illness
Humans
Incidence
Goals
Źródło :
Lancet, 393(10178), 1331 - 1384. Elsevier Limited
Opis pliku :
application/pdf; application/octet-stream
Tytuł :
In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin
Autorzy :
Dijkstra, J.A.
Laan, T. van der
Akkerman, O.W.
Bolhuis, M.S.
Lange, W.C. de
Kosterink, J.G.
Werf, T.S. van der
Alffenaar, J.W.C.
Soolingen, D. van
Pokaż więcej
Temat :
Microbial Sensitivity Tests
Tuberculosis, Multidrug-Resistant
biochemical phenomena, metabolism, and nutrition
Glycopeptides
Susceptibility
carbohydrates (lipids)
Mycobacterium tuberculosis/drug effects
Amikacin/pharmacology
Journal Article
Capreomycin/pharmacology
Kanamycin/pharmacology
Źródło :
Antimicrobial Agents and Chemotherapy, 62
Antimicrobial Agents and Chemotherapy, 62(3). American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 62(3). AMER SOC MICROBIOLOGY
Opis pliku :
application/pdf
Tytuł :
Quadruple-first line drug resistance in Mycobacterium tuberculosis in Vietnam: What can we learn from genes?
Autorzy :
Nguyen, Huy Quang
Nguyen, Nhung Viet
Contamin, Lucie
Tran, Thanh Hoa Thi
Vu, Thuong Thi
Nguyen, Hung Van
Nguyen, Ngoc Lan Thi
Nguyen, Son Thai
Dang, Anh Duc
Bañuls, Anne-Laure
Nguyen, Van Anh Thi
Pokaż więcej
Temat :
Spoligotyping
MIRU-VNTR
Mycobacterium tuberculosis
Second line drugs
First line drugs
Extensively drug resistance
Drug susceptibility testing
Drug resistance-associated mutations
MESH: Antitubercular Agents/pharmacology
MESH: Bacterial Proteins/genetics
MESH: Oxidoreductases/genetics
MESH: Pentosyltransferases/genetics
MESH: Bacterial Typing Techniques
MESH: Ribosomal Proteins/genetics
MESH: Rifampin/pharmacology
MESH: Streptomycin/pharmacology
MESH: Vietnam
MESH: Catalase/genetics
MESH: DNA Gyrase/genetics
MESH: DNA-Directed RNA Polymerases/genetics
MESH: Genetic Fitness
MESH: Drug Resistance, Multiple, Bacterial/genetics
MESH: Ethambutol/pharmacology
MESH: Extensively Drug-Resistant Tuberculosis/microbiology
MESH: Gene Expression
MESH: Genetic Variation
MESH: Humans
MESH: Isoniazid/pharmacology
MESH: Mutation
MESH: Mycobacterium tuberculosis/drug effects
MESH: Mycobacterium tuberculosis/genetics
MESH: Mycobacterium tuberculosis/isolation & purification
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Źródło :
Infection, Genetics and Evolution
Infection, Genetics and Evolution, Elsevier, 2017, 50, pp.55-61. ⟨10.1016/j.meegid.2017.02.012⟩
Tytuł :
Isoniazid resistant tuberculosis- a cause for concern?
Autorzy :
Stagg, H R
Lipman, M C
McHugh, T D
Jenkins, H E
Pokaż więcej
Temat :
Global Health
Phenotype
Mycobacterium tuberculosis/drug effects
Isoniazid/therapeutic use
bacterial infections and mycoses
National Health Programs
Treatment Outcome
Tuberculosis, Multidrug-Resistant/diagnosis
Article
Genotype
Antitubercular Agents/therapeutic use
Tuberculosis/diagnosis
Humans
Źródło :
Stagg, H R, Lipman, M C, McHugh, T D & Jenkins, H E 2017, ' Isoniazid-resistant tuberculosis: a cause for concern? ', The international journal of tuberculosis and lung disease, vol. 21, no. 2, pp. 129-139 . https://doi.org/10.5588/ijtld.16.0716
Opis pliku :
application/pdf
Tytuł :
Modulation of host defence against bacterial and viral infections by omega-3 polyunsaturated fatty acids
Autorzy :
Husson, Marie-Odile
Ley, Delphine
Portal, Céline
Gottrand, Madeleine
Hueso, Thomas
Desseyn, Jean-Luc
gottrand, frederic
Pokaż więcej
Temat :
Mesh:Staphylococcal Infections/drug therapy
Mesh:Mycobacterium tuberculosis/drug effects
Administration
Mycobacterium tuberculosis
Mesh:Herpes Simplex/drug therapy
Sciences du Vivant [q-bio]
Mesh:Inflammation/prevention & control
Mesh:Chronic Disease/prevention & control
Mesh:Citrobacter rodentium/drug effects
Prevention
Staphylococcus aureus
Mesh:Chronic Disease/drug therapy
Mesh:Bacterial Infections/microbiology
Mesh:Mycobacterium tuberculosis/immunology
Mesh:Citrobacter rodentium/immunology
Mesh:Administration
Mesh:Dietary Supplements
Chronic Disease
Mesh:Bacterial Infections/drug therapy
Helicobacter hepaticus
Virus Diseases
Mesh:Omega-3/therapeutic use
n-3 LC-PUFA
Immunomodulatory
Mesh:Fatty Acids
Mesh:Virus Diseases/virology
Infection
Mesh:Omega-3/adverse effects
Mesh:Humans
Mesh:Staphylococcal Infections/prevention & control
Bacterial Infections
Mesh:Omega-3/administration & dosage
Mesh:Staphylococcus aureus/drug effects
Mesh:Helicobacter hepaticus/drug effects
Omega-3
Inflammation
Mesh:Staphylococcus aureus/immunology
Dietary Supplements
Anti-inflammatory
Outcome
Fatty Acids
Mesh:Inflammation/drug therapy
Staphylococcal Infections
Mesh:Herpes Simplex/prevention & control
Herpes Simplex
Mesh:Bacterial Infections/prevention & control
Mesh:Virus Diseases/prevention & control
Mesh:Helicobacter hepaticus/immunology
Mesh:Virus Diseases/drug therapy
Citrobacter rodentium
Oral
Humans
Mesh:Herpes Simplex/virology
Mesh:Oral
Tytuł :
What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis?:A systematic review and network meta-analysis
Autorzy :
Zhao, H
Stagg, H R
Harris, R J
Hatherell, H-A
Obach, D
Tsuchiya, N
Kranzer, K
Nikolayevskyy, V
Kim, J
Lipman, M C
Abubakar, I
Pokaż więcej
Temat :
Publication Bias
Tuberculosis/drug therapy
Drug Resistance, Bacterial
Mycobacterium tuberculosis/drug effects
Antitubercular Agents/pharmacology
Tuberculosis
Clinical Epidemiology
Isoniazid/pharmacology
Drug Therapy, Combination
Randomized Controlled Trials as Topic/methods
Humans
Źródło :
Stagg, H R, Harris, R J, Hatherell, H-A, Obach, D, Zhao, H, Tsuchiya, N, Kranzer, K, Nikolayevskyy, V, Kim, J, Lipman, M C & Abubakar, I 2016, ' What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis ', Thorax, vol. 71, no. 10, pp. 940-9 . https://doi.org/10.1136/thoraxjnl-2015-208262
Thorax, 71, Article Thorax 2016;71:. (2016)
Opis pliku :
text; application/pdf
Tytuł :
MDR-TB Outbreak among HIV-Negative Tunisian Patients followed during 11 Years
Autorzy :
Naira Dekhil
Nedra Meftahi
Besma Mhenni
Saloua Ben Fraj
Raja Haltiti
Sameh Belhaj
Helmi Mardassi
Pokaż więcej
Temat :
Cancer Treatment
MESH: Tuberculosis, Multidrug-Resistant/microbiology
Pharmaceutics
MESH: Male
Bacteria
Infectious Diseases
MESH: Mycobacterium tuberculosis/genetics
MESH: Tuberculosis, Multidrug-Resistant/drug therapy
Mycobacterium Tuberculosis
Restriction Fragment Length Polymorphism Analysis
Chemotherapy
Oncology
Antimicrobial Resistance
Molecular Biology Techniques
Gene Mapping
Pharmacology
MESH: Female
MESH: Adult
Actinobacteria
Biology and Life Sciences
Tuberculosis
Bacterial Diseases
MESH: Antitubercular Agents/therapeutic use
MESH: Disease Outbreaks
Science
Multi-Drug-Resistant Tuberculosis
Restriction Fragment Mapping
Organisms
Molecular Biology
Microbial Control
Research Article
MESH: HIV Seronegativity
MESH: Tuberculosis, Multidrug-Resistant/epidemiology
MESH: Antitubercular Agents/pharmacology
Clinical Medicine
MESH: Young Adult
Clinical Oncology
Drug Therapy
Research and Analysis Methods
Microbiology
MESH: Humans
Medicine
Tropical Diseases
[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology
MESH: Mycobacterium tuberculosis/drug effects
Medicine and Health Sciences
MESH: Tunisia/epidemiology
MESH: Microbial Sensitivity Tests
Źródło :
PLoS ONE, Public Library of Science, 2016, 11 (4), pp.e0153983. ⟨10.1371/journal.pone.0153983⟩
PLoS ONE, Vol 11, Iss 4, p e0153983 (2016)
Tytuł :
Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia
Autorzy :
Stagg, Helen R
White, Peter J
Riekstiņa, Vija
Cīrule, Andra
Šķenders, Ģirts
Leimane, Vaira
Kuksa, Liga
Dravniece, Gunta
Brown, James
Jackson, Charlotte
Pokaż więcej
Temat :
multidrug resistance
1117 Public Health And Health Services
bacteria
Xpert MTB/RIF
MDR TB
Infectious Diseases
Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia
Young Adult
Research
1103 Clinical Sciences
antimicrobial resistance
Antibiotics, Antitubercular/pharmacology
Latvia
tuberculosis and other mycobacteria
Infectious and parasitic diseases
MODEL
Female
time to treatment initiation
Immunology
molecular diagnostics
Tuberculin Test/methods
Mycobacterium tuberculosis/drug effects
Life Sciences & Biomedicine
Drug Resistance, Microbial
Microbiology
pulmonary
Time-to-Treatment
Medicine
multidrug-resistant tuberculosis
Middle Aged
Tuberculosis, Multidrug-Resistant/diagnosis
1108 Medical Microbiology
RC109-216
Science & Technology
rifampin
Adolescent
Adult
Rifampin/pharmacology
Humans
Male
Źródło :
Emerging Infectious Diseases, Vol 22, Iss 3, Pp 482-490 (2016)
Stagg, H R, White, P J, Riekstiņa, V, Cīrule, A, Šķenders, Ģ, Leimane, V, Kuksa, L, Dravniece, G, Brown, J & Jackson, C 2016, ' Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia ', Emerging Infectious Diseases, vol. 22, no. 3, pp. 482-90 . https://doi.org/10.3201/eid2203.151227
Emerging Infectious Diseases
Emerging Infectious Diseases, 22 (3) pp. 482-490. (2016)
Opis pliku :
application/pdf; text

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies